Malaria vaccine R&D in the Decade of Vaccines: breakthroughs, challenges and opportunities.
暂无分享,去创建一个
D. Kaslow | C. Loucq | C. Chitnis | V. Moorthy | Chetan E Chitnis | A. Birkett | Christian Loucq | Vasee S Moorthy | Ashley J Birkett | David C Kaslow
[1] B. Genton,et al. A review of malaria vaccine clinical projects based on the WHO rainbow table , 2012, Malaria Journal.
[2] Jonathan E. Allen,et al. Genome sequence of the human malaria parasite Plasmodium falciparum , 2002, Nature.
[3] Peter G. Smith,et al. MALVAC 2008: Measures of efficacy of malaria vaccines in phase 2b and phase 3 trials--scientific, regulatory and public health perspectives. , 2009, Vaccine.
[4] M. Enserink,et al. Malaria. Did they really say ... eradication? , 2007, Science.
[5] D. Schellenberg,et al. A Research Agenda for Malaria Eradication: Health Systems and Operational Research , 2011, PLoS medicine.
[6] A. Cowman,et al. Erythrocyte and reticulocyte binding-like proteins of Plasmodium falciparum. , 2012, Trends in parasitology.
[7] P. Druilhe,et al. Pre-Clinical Assessment of Novel Multivalent MSP3 Malaria Vaccine Constructs , 2011, PloS one.
[8] M. Fay,et al. Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51 , 2008, PloS one.
[9] Clyde Df. Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-75. , 1990 .
[10] V. A. Stewart,et al. Priming with an Adenovirus 35-Circumsporozoite Protein (CS) Vaccine followed by RTS,S/AS01B Boosting Significantly Improves Immunogenicity to Plasmodium falciparum CS Compared to That with Either Malaria Vaccine Alone , 2007, Infection and Immunity.
[11] O. Doumbo,et al. A field trial to assess a blood-stage malaria vaccine. , 2011, The New England journal of medicine.
[12] V. A. Stewart,et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. , 2009, The Journal of infectious diseases.
[13] R. Sauerwein,et al. Experimental human challenge infections can accelerate clinical malaria vaccine development , 2010, Nature Reviews Immunology.
[14] D. Leboulleux,et al. Aligning new interventions with developing country health systems: Target product profiles, presentation, and clinical trial design , 2012, Global public health.
[15] Pedro Alonso,et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. , 2011, The New England journal of medicine.
[16] Kwaku Poku Asante,et al. Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. , 2010, The Journal of infectious diseases.
[17] John Sidney,et al. Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[18] J. Stockman. First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children , 2013 .
[19] S. Hoffman,et al. Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. , 2007, The Journal of infectious diseases.
[20] S. Hoffman,et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. , 1998, The Journal of infectious diseases.
[21] J. Sattabongkot,et al. Establishment of a human hepatocyte line that supports in vitro development of the exo-erythrocytic stages of the malaria parasites Plasmodium falciparum and P. vivax. , 2006, The American journal of tropical medicine and hygiene.
[22] Thomas A. Smith,et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. , 2002, The Journal of infectious diseases.
[23] Patricia De la Vega,et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. , 2002, The Journal of infectious diseases.
[24] P. Andersen,et al. Identification and Characterization of B-Cell Epitopes in the DBL4ε Domain of VAR2CSA , 2012, PloS one.
[25] A. Hill,et al. Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? , 2012, Human vaccines & immunotherapeutics.
[26] Prashant Yadav,et al. A Research Agenda for Malaria Eradication: Vaccines , 2019 .
[27] J. Stockman. A Field Trial to Assess a Blood-Stage Malaria Vaccine , 2013 .
[28] R. Sauerwein,et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study , 2011, The Lancet.
[29] David L Smith,et al. Revisiting the Basic Reproductive Number for Malaria and Its Implications for Malaria Control , 2007, PLoS biology.
[30] Nicolas Maire,et al. What Should Vaccine Developers Ask? Simulation of the Effectiveness of Malaria Vaccines , 2008, PloS one.
[31] D. Conway,et al. Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis , 2008, The Lancet.
[32] David L. Smith,et al. A new world malaria map: Plasmodium falciparum endemicity in 2010 , 2011, Malaria Journal.
[33] M. Chen-Mok,et al. Successful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donors. , 2009, The American journal of tropical medicine and hygiene.
[34] E. R. James,et al. Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8+ T Cell Immunity , 2011, Science.
[35] D. Webster,et al. A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. , 2006, Vaccine.
[36] K. Marsh,et al. Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA. , 2009, Vaccine.
[37] Ogobara K. Doumbo,et al. A Research Agenda to Underpin Malaria Eradication , 2011, PLoS medicine.
[38] Conor P. Cahill,et al. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa , 2011, Malaria Journal.
[39] M. Tanner,et al. Virosome-Formulated Plasmodium falciparum AMA-1 & CSP Derived Peptides as Malaria Vaccine: Randomized Phase 1b Trial in Semi-Immune Adults & Children , 2011, PloS one.
[40] Joe D. Cohen,et al. Development of the RTS,S/AS malaria candidate vaccine. , 2009, Vaccine.
[41] R. Snow,et al. Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya , 2008, The Lancet.
[42] David L. Smith,et al. A World Malaria Map: Plasmodium falciparum Endemicity in 2007 , 2009, PLoS medicine.
[43] David L. Smith,et al. A Long Neglected World Malaria Map: Plasmodium vivax Endemicity in 2010 , 2012, PLoS neglected tropical diseases.
[44] R. Newman,et al. Malaria vaccine technology roadmap , 2013, The Lancet.
[45] V. Nussenzweig,et al. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria , 1989, Nature.
[46] A. García-Sastre,et al. Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[47] T. Richie,et al. Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers. , 2011, The American journal of tropical medicine and hygiene.
[48] Nirbhay Kumar,et al. Transgenic Rodent Plasmodium berghei Parasites as Tools for Assessment of Functional Immunogenicity and Optimization of Human Malaria Vaccines , 2008, Eukaryotic Cell.
[49] D. Clyde. Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-75. , 1990, Bulletin of the World Health Organization.
[50] B. Genton,et al. MALVAC 2009: progress and challenges in development of whole organism malaria vaccines for endemic countries, 3-4 June 2009, Dakar, Senegal. , 2010, Vaccine.
[51] Jonathan Crabtree,et al. Comparative genomics of the neglected human malaria parasite Plasmodium vivax , 2008, Nature.
[52] F. Lunel,et al. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages , 1995, The Journal of Experimental Medicine.
[53] Adrian J F Luty,et al. Protection against a malaria challenge by sporozoite inoculation. , 2009, The New England journal of medicine.
[54] P. Chomez,et al. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives , 2007, Expert review of vaccines.
[55] Weltgesundheitsorganisation. World malaria report , 2005 .
[56] G. Stygall. “Did They Really Say That?” , 2008 .
[57] Joe D. Cohen,et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. , 1997, The New England journal of medicine.
[58] S. Hoffman,et al. Controlled Human Malaria Infections by Intradermal Injection of Cryopreserved Plasmodium falciparum Sporozoites , 2013, The American journal of tropical medicine and hygiene.
[59] K. Marsh,et al. Correction: Corrigendum: The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody , 2011, Nature Communications.
[60] Johan Vekemans,et al. Le candidat vaccin antipaludique RTS,S/AS est entr en essais cliniques de phase III , 2010 .
[61] Kwaku Poku Asante,et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. , 2012, The New England journal of medicine.
[62] J. Brewer,et al. What can transgenic parasites tell us about the development of Plasmodium‐specific immune responses? , 2008, Parasite immunology.
[63] Kwaku Poku Asante,et al. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. , 2011, The Lancet. Infectious diseases.
[64] Philip Awadalla,et al. Global genetic diversity and evolution of var genes associated with placental and severe childhood malaria. , 2006, Molecular and biochemical parasitology.
[65] J. Aponte,et al. Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS , S / AS 01 malaria vaccine in African children , 2011 .
[66] R. Sauerwein,et al. A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines. , 2012, Vaccine.
[67] J. Sattabongkot,et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. , 2005, Vaccine.
[68] M. Enserink,et al. Did They Really Say ... Eradication? , 2007, Science.
[69] P. Bhanot,et al. Cutting Edge: A New Tool to Evaluate Human Pre-Erythrocytic Malaria Vaccines: Rodent Parasites Bearing a Hybrid Plasmodium falciparum Circumsporozoite Protein1 , 2002, The Journal of Immunology.
[70] Thor G. Theander,et al. Evidence for the Involvement of VAR2CSA in Pregnancy-associated Malaria , 2004, The Journal of experimental medicine.
[71] Peter G. Smith,et al. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. , 2007, Vaccine.